Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study

Oncology. 1989;46(2):88-90. doi: 10.1159/000226691.

Abstract

Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals. Two patients had a partial response (6%) and 14 a stable disease (47%). The toxicity of this regimen was essentially digestive with 30% of grade 3 or 4 nausea and vomiting. In spite of the reported active and synergistic action of drug association in colorectal carcinoma, this treatment schedule is not better than 5-FU alone. Moreover, gastrointestinal toxicity is increased.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Dacarbazine / administration & dosage
  • Drug Administration Schedule
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage*
  • Humans
  • Male
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage

Substances

  • Mitomycins
  • Mitomycin
  • Dacarbazine
  • Fluorouracil